Assessment of treatment response in hepatocellular carcinoma: a review of the literature

被引：0

作者：

Maida, Marcello ^{[1
]}

Cabibbo, Giuseppe ^{[1
]}

Brancatelli, Giuseppe ^{[2
]}

Genco, Chiara ^{[1
]}

Alessi, Nicola ^{[1
]}

Genova, Claudio ^{[2
]}

Romano, Piero ^{[2
]}

Raineri, Maurizio ^{[3
]}

Giarratano, Antonello ^{[3
]}

Midiri, Massimo ^{[2
]}

Camma, Calogero ^{[1
]}

机构：

[1] Univ Palermo, DIBIMIS, Gastroenterol Sect, Palermo, Italy

[2] Univ Palermo, DIBIMEF, Dept Radiol, Palermo, Italy

[3] Univ Palermo, DIBIMEF, Intens Care & Emergency Inst, Palermo, Italy

来源：

FUTURE ONCOLOGY | 2013年 / 9卷 / 06期

关键词：

hepatocellular carcinoma; mRECIST; response criteria; RANDOMIZED CONTROLLED-TRIAL; LONG-ACTING OCTREOTIDE; SYMPTOMATIC TREATMENT; EVALUATION CRITERIA; INTRAOBSERVER VARIABILITY; INTERFERON-ALPHA; MODIFIED RECIST; TUMOR RESPONSE; TAMOXIFEN; CANCER;

D O I：

10.2217/FON.13.33

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) has a high incidence all over the world. Even if the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and could have a key role in clinical management. Since 1950 several radiological response criteria have been applied; however, it was not until 2000 that specific criteria for HCC were introduced by the European Association for the Study of the Liver (EASL), and these were then standardized in 2010 with the development of the modified Response Evaluation Criteria for Solid Tumors (mRECIST) for HCC. The purpose of this brief review is to compare data in literature regarding the application and the performance of mRECIST in clinical practice, and to discuss unclear and open issues.

引用

页码：845 / 854

页数：10

共 66 条

[61] Measuring the clinical response. What does it mean?
Therasse, P
[J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (14) : 1817 - 1823
[62] RECIST revisited: A review of validation studies on tumour assessment
Therasse, P.
Eisenhauer, E. A.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) : 1031 - 1039
[63] Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
[64] Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors
Villa, E
Ferretti, I
Grottola, A
Buttafoco, P
Del Buono, MG
Giannini, F
Manno, M
Bertani, H
Dugani, A
Manenti, F
[J]. BRITISH JOURNAL OF CANCER, 2001, 84 (07) : 881 - 885
[65] A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma
Yuen, MF
Poon, RTP
Lai, CL
Fan, ST
Lo, CM
Wong, KW
Wong, WM
Wong, BCY
[J]. HEPATOLOGY, 2002, 36 (03) : 687 - 691
[66] Zubrod CG., 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5

← 1 2 3 4 5 6 7 →